Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iEuroEwing international protocol for treatment optimization in Ewing sarcoma
MOH_2023-06-18_012676Phase 3Not yet recruiting
- Sponsor
- ד"ר דרור לוין
- Start
- Feb 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide and 1 more in Ewing sarcoma and Ewing-like sarcoma (6 arms), sponsored by ד"ר דרור לוין. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
vincristinedoxorubicincyclophosphamideifosfamideetoposide
03
Conditions
Ewing sarcomaEwing-like sarcoma
Beyond the preview
Go deeper on MOH_2023-06-18_012676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-18_012676.